STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Aims: Doxorubicin (DR), a widely prescribed chemotherapy, has an unfortunate side effect of cardiotoxicity resulting from DNA damage and cardiac cell death. Cardiac atrophy, fibrosis and a cytotoxic CD8+ T-cell response, alongside increased cardiac and circulating interferon-inducible chemokines are hallmarks for DR cardiotoxicity. Methods and results: We discovered that the activation of the stimulator of interferon genes (STING) in several distinct cardiac cell compartments is central to CD8+ T-cell cardiotropism and DR cardiotoxicity. DR activates STING in cardiac fibroblasts, endothelial cells (ECs), and myeloid cells in vivo and in vitro. Myeloid STING is required for CD8+ T-cell activation and cardiotropism, whereas EC-STING mediates CD8+ T-cell cardiotropism towards CXCL9/10 and transendothelial migration. In contrast, cardiac fibroblast STING is dispensable for the cardiac CD8+ T-cell immune response but drives fibroblast transformation. We report CXCR3+ T cells and CXCL9/CXCL10 are more abundant in the hearts of DR cardiotoxicity patients. Conclusion: Our work positions STING as a cell-specific driver of CD8+ T-cell cardiac inflammation and fibroblast activation in DR cardiotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dunphy, G., Flannery, S. M., Almine, J. F., Connolly, D. J., Paulus, C., Jønsson, K. L., Jakobsen, M. R., Nevels, M. M., Bowie, A. G., & Unterholzner, L. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.034 · Cited by 648
Research works printed but not linked: 35
- Sritharan, 2021, A comprehensive review on time-tested anticancer drug doxorubicin, Life Sci, 278, 119527, 10.1016/j.lfs.2021.119527 · DOI · Paper page
- Henriksen, 2018, Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention, Heart, 104, 971, 10.1136/heartjnl-2017-312103 · DOI · Paper page
- Nitiss, 2009, Targeting DNA topoisomerase II in cancer chemotherapy, Nat Rev Cancer, 9, 338, 10.1038/nrc2607 · DOI · Paper page
- Kim, 2006, Doxorubicin-induced reactive oxygen species generation and intracellular Ca2 + increase are reciprocally modulated in rat cardiomyocytes, Exp Mol Med, 38, 535, 10.1038/emm.2006.63 · DOI · Paper page
- Bayer, 2024, Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction, Nat Cardiovasc Res, 3, 970, 10.1038/s44161-024-00507-y · DOI
- Christidi, 2021, Regulated cell death pathways in doxorubicin-induced cardiotoxicity, Cell Death Dis, 12, 1, 10.1038/s41419-021-03614-x · DOI · Paper page
- Upshaw, 2024, Dexrazoxane to prevent cardiotoxicity in adults treated with anthracyclines, JACC CardioOncol, 6, 322, 10.1016/j.jaccao.2024.02.004 · DOI · Paper page
- Macedo, 2019, Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer, JACC CardioOncol, 1, 68, 10.1016/j.jaccao.2019.08.003 · DOI · Paper page
- Decout, 2021, The cGAS–STING pathway as a therapeutic target in inflammatory diseases, Nat Rev Immunol, 21, 548, 10.1038/s41577-021-00524-z · DOI · Paper page
- Anastasiou, 2021, Endothelial STING controls T cell transmigration in an IFN-I dependent manner, JCI Insight, 6, e149346, 10.1172/jci.insight.149346 · DOI
- Shamseddine, 2022, Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies, J Exp Med, 220, e20220809, 10.1084/jem.20220809 · DOI
- Luo, 2023, Critical role of the cGAS-STING pathway in doxorubicin-induced cardiotoxicity, Circ Res, 132, e223, 10.1161/CIRCRESAHA.122.321587 · DOI · Paper page
- Lei, 2023, Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity, Cell, 186, 3013, 10.1016/j.cell.2023.05.039 · DOI · Paper page
- Jin, 2011, MPYS is required for IRF3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers c-di-AMP and c-di-GMP, J Immunol, 187, 2595, 10.4049/jimmunol.1100088 · DOI · Paper page
- Sanders, 2025, Endothelial cell stimulator of i genes regulates IL-6 production and is required for pathologic cardiac hypertrophy and contractile dysfunction in experimental heart failure, Am J Pathol, 195, 1788, 10.1016/j.ajpath.2025.06.004 · DOI
- Pham, 2025, Opposing roles for myeloid and smooth muscle cell STING in pulmonary hypertension, JCI Insight, 10, 10.1172/jci.insight.184792 · DOI
- Ngwenyama, 2022, Antigen presentation by cardiac fibroblasts promotes cardiac dysfunction, Nat Cardiovasc Res, 1, 761, 10.1038/s44161-022-00116-7 · DOI · Paper page
- Ngwenyama, 2019, CXCR3 regulates CD4+ T cell cardiotropism in pressure overload–induced cardiac dysfunction, JCI Insight, 4, e125527, 10.1172/jci.insight.125527 · DOI · Paper page
- Luscinskas, 1989, Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium, J Immunol, 142, 2257, 10.4049/jimmunol.142.7.2257 · DOI · Paper page
- Bayer, 2023, T-cell MyD88 is a novel regulator of cardiac fibrosis through modulation of T-cell activation, Circ Res, 133, 412, 10.1161/CIRCRESAHA.123.323030 · DOI
- Chen, 2018, Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure, Nat Med, 24, 1225, 10.1038/s41591-018-0046-2 · DOI · Paper page
- Liu, 2026, An integrated approach using CITE-sequencing and plasma proteomics reveals immune signatures of doxorubicin cardiotoxicity, Circulation
- Huang, 2025, Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis, Circ Res, 136, 473, 10.1161/CIRCRESAHA.124.325652 · DOI
- Clausen, 1999, Conditional gene targeting in macrophages and granulocytes using LysMcre mice, Transgenic Res, 8, 265, 10.1023/A:1008942828960 · DOI · Paper page
- Farber, 1997, Mig and IP-10: CXC chemokines that target lymphocytes, J Leukoc Biol, 61, 246, 10.1002/jlb.61.3.246 · DOI · Paper page
- Guo, 2025, Human single-nucleus RNA sequencing identifies CD47 as a therapeutic target for doxorubicin-induced cardiomyopathy, Circulation, 152, 661, 10.1161/CIRCULATIONAHA.124.071217 · DOI
- Lucero, 2026, Cardiomyocyte β-arrestins mediate inflammation and cGAS-STING activation in CVB3 viral myocarditis, Am J Physiol Heart Circ Physiol, 330, H499, 10.1152/ajpheart.00589.2025 · DOI
- Wahyuni, 2022, CXCL10 is a novel anti-angiogenic factor downstream of p53 in cardiomyocytes, Physiol Rep, 10, e15304, 10.14814/phy2.15304 · doi:10.14814/phy2.15304
- Corbera-Bellalta, 2016, Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis, Ann Rheum Dis, 75, 1177, 10.1136/annrheumdis-2015-208371 · DOI
- Liu, 2012, Endoplasmic Reticulum stress regulates the innate immunity critical transcription factor IRF3, J Immunol, 189, 4630, 10.4049/jimmunol.1102737 · DOI · Paper page
- Paludan, 2013, Immune sensing of DNA, Immunity, 38, 870, 10.1016/j.immuni.2013.05.004 · DOI · Paper page
- de Graaf, 2018, NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid, Hepatol Commun, 2, 492, 10.1002/hep4.1170 · DOI · Paper page
- 2012, A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis, Arthritis Rheum, 64, 1730, 10.1002/art.34330 · DOI · Paper page
- Christen, 2023, Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes, Clin Exp Immunol, 214, 131, 10.1093/cei/uxad083 · DOI
- Shengchao, 2024, Long-term CXCR3 antagonist AMG487 mitigated acute graft-versus-host disease by inhibiting T cell activation in a murine model, Transpl Immunol, 87, 102128, 10.1016/j.trim.2024.102128 · doi:10.1016/j.trim.2024.102128
Metadata
- Authors
- Bayer, A. L., Zambrano, M. A., Emig, R., Sanders, E., Smolgovsky, S., Wagner, N., Bedi, K. C., Bhave, S., Kapur, N. K., Margulies, K. B., Asnani, A., & Alcaide, P.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2026-06
- Volume
- 122
- Issue
- 9
- Pages
- 1224-1242
- ISSN
- 0008-6363
- 1755-3245
- Cited by
- 3
- References
- 1
- Language
- en
- Funders
- National Institute of Health (R01 HL144477, HL165725)
- Tufts Springboard Tier 1 Grant (HL162200, R01 HL159089, R01 HL133215, HL159907, HL175911, 1187744, R01 HL163172, HL149891, HL105993, R01 HL089847)
- German Research Foundation
- Walter Benjamin programme (539486371)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy. https://app.cochat.ai/papers/10.1093/cvr/cvag098
- The paper
- Bayer, A. L., Zambrano, M. A., Emig, R., Sanders, E., Smolgovsky, S., Wagner, N., Bedi, K. C., Bhave, S., Kapur, N. K., Margulies, K. B., Asnani, A., & Alcaide, P. (2026). STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy. Cardiovascular Research. https://doi.org/10.1093/cvr/cvag098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.